Industrial robot producer Rethink Robotics had raised $136m from backers including GE Ventures but has ceased trading after failing to close a planned acquisition deal.

Alphabet subsidiary Google has bought RGA-backed customer service chatbot developer Onward to integrate the latter's AI tools with its own technology.

Holiday accommodation booking service Oasis Collections has been picked up by Vacasa after raising $35m in funding from investors including Hyatt and AccorHotels.

The SoftBank-backed precision oncology test developer floated above its range and saw its share price rise 69% on the first day of trading.

Cellular therapy developer Gamida Cell, which counts Novartis as its largest investor, has filed for a $69m initial public offering.

Merck & Co and Takeda are in line for exits when drug developer NGM Biopharmaceuticals lists on the Nasdaq Global Select Market.

The SIG China-backed mobile app developer raised $52.2m despite floating at the bottom of the IPO's range.

The Eli Lilly-backed immuno-oncology product developer floated at the top of its range, with Bluebird Bio investing $10m.

Immunotherapy developer Sutro Biopharma has floated on the Nasdaq Global Market, providing exits for Merck & Co, Celgene, Amgen and Eli Lilly.

The lending platform's existing shareholders, which include Rocket Internet, sold $184m in shares as part of the offering.